Outlook Therapeutics (OTLK) Q3 2026 earnings summary

Executive summary

• FDA approval of LYTENAVA marks it as the only FDA-approved ophthalmic bevacizumab for wet AMD in the U.S., opening significant commercial opportunities and positioning the company for growth.

• U.S. commercial launch preparations are underway, targeting retina specialists and high-volume practices, with a focus on payer engagement, reimbursement clarity, and reliable supply.

• LYTENAVA is also being commercialized in Germany, Austria, and the U.K., with further launches planned in the Netherlands and Switzerland as part of ongoing European expansion.

• $51.1 million in net proceeds was raised from an August 2026 public offering to support U.S. commercialization and working capital.

• LYTENAVA is positioned as a differentiated product, addressing the need for an FDA-approved alternative to repackaged off-label bevacizumab.

Financial highlights

• Adjusted net loss for Q3 FY2026 was $10.9 million ($0.09 per share), improved from $15.8 million ($0.44 per share) in Q3 FY2025, excluding non-cash and non-recurring items.

• Net loss attributable to common stockholders for Q3 FY2026 was $20.3 million ($0.15 per share), compared to $20.2 million ($0.55 per share) in Q3 FY2025.

• Cash and equivalents stood at $11.2 million as of June 30, 2026, not including $51.1 million in net proceeds from the August 2026 public offering.

• Net revenue for the nine months ended June 30, 2026 was negative $1.1 million, compared to $1.5 million for the same period in 2025, primarily due to increased returns reserves and administrative fees.

• Operating cash outflow for the nine months ended June 30, 2026 was $43.8 million.

Outlook and guidance

• Projected U.S. net revenue for LYTENAVA's first 12 months post-launch is $50–75 million, with Europe contributing 10–15%.

• Peak U.S. annual sales potential for LYTENAVA is estimated at over $500 million by 2030.

• Launch ramp expected to be progressive, with acceleration tied to the anticipated permanent J-code in April 2027.

• Management does not believe existing cash and offering proceeds are sufficient to fund operations for 12 months, raising substantial doubt about the ability to continue as a going concern; additional financing will be required.

• Focus remains on U.S. launch and continued European expansion.